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Abstract
Angiogenesis is disregulated in many diseased states, most notably in cancer. An emerging strategy for the
development of therapies targeting tumor-associated angiogenesis is to harness the potential of nanotechnology
to improve the pharmacology of chemotherapeutics, including anti-angiogenic agents. Nanoparticles confer several
advantages over that of free drugs, including their capability to carry high payloads of therapeutic agents, confer
increased half-life and reduced toxicity to the drugs, and provide means for selective targeting of the tumor tissue
and vasculature. The plethora of nanovectors available, in addition to the various methods available to combine
them with anti-angiogenic drugs, allows researchers to fine-tune the pharmacological profile of the drugs ad
infinitum. Use of nanovectors has also opened up novel avenues for non-invasive imaging of tumor angiogenesis.
Herein, we review the types of nanovector and therapeutic/diagnostic agent combinations used in targeting tumor
angiogenesis.
Introduction
Since Judah Folkman emphasized the ‘angiogenic switch’
hypothesis for tumor progression in 1991, there has been
a tremendous surge in targeting angiogenesis for cancer
therapeutics [1]. In the past 30 years, many advances
have been made in the field, with the elucidation of var-
ious angiogenic molecules that could be targeted to halt
angiogenesis, and hence, tumor progression. Angiogen-
esis, the formation of new capillaries from preexisting
vessels, is crucial for ensuring normal embryonic vascular
development of all vertebrates, as well as regulating phy-
siological processes such as menses and wound healing
in adults [2-4]. Deregulation of angiogenesis hence
underlies pathologies characterized by vessel overgrowth
(e.g. cancer) as well as vessel insufficiency (e.g. cardiovas-
cular disease, CVD) [4].
It is now well-established that without angiogenesis,
tumors cannot grow more than 2 mm in diameter [5-7].
Studies in breast cancer patients have showed that angio-
genesis positively correlates with the degree of metastasis,
tumor recurrence and shorter survival rates, thus demon-
strating the value of angiogenesis as a prognostic cancer
marker [1,8]. Tumor angiogenesis essentially entails the
same sequences of events as physiological angiogenesis,
however, the latter proceeds in an uncontrolled and
excessive manner giving rise to leaky and tortuous vessels
that are in a constant state of inflammation [6,9]. This is
mainly due by an upregulation of angiogenic cytokines
and growth factors, most notably the vascular endothelial
cell growth factor (VEGF) and Angiopoietin (Ang)
families, as well as integrins [10-12]. Integrin avb3 is the
best-characterized heterodimer that is upregulated in
most cancer settings, both on the vasculature and on the
tumor cells themselves [13,14]. It is hence not surprising
that these molecules are often targeted in both experi-
mental and clinical cancer settings.
As such, the first U.S. Food and Drug Administration
(FDA) approved anti-angiogenic therapy was the mono-
clonal antibody Bevacizumab (Avastin), that targets
VEGF proteins overexpressed on colorectal cancer cells
and their vasculature [15,16]. In spite of the clinical suc-
cess of Avastin, the majority of other such anti-angio-
genic therapeutic agents have yet to pass phase II
clinical trials, suggesting a new paradigm is essential to
target aberrant angiogenesis.
Moving away from conventional chemotherapy
Targeting aberrant angiogenesis for cancer therapy
Development of anti-angiogenesis therapy is based on
either drugs that prevent the formation of new blood
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tin, angiostatin), or drugs that damage existing blood
vessels (e.g. combretastatin) [17]. The underlying
mechanisms of action of these anti-angiogenic drugs are
either direct, by targeting endothelial receptors, or indir-
ect, by targeting angiogenic cytokines. These mechan-
isms of action differ from those of conventional
chemotherapy in the following ways: (i) selective target-
ing of the tumor-associated vasculature instead of the
tumor cells themselves; (ii) increased bioavailability of
tumor endothelial cells to systemically-administered
anti-angiogenic drugs due to their direct contact with
blood circulation, whereas tumor cells residing in the
distant tumor tissue are less accessible to conventional
chemotherapeutic agents; (iii) whereas conventional che-
motherapy uses the principle of maximum tolerated
dose (MTD), anti-angiogenic therapy is administered in
lower doses at a relatively more frequent schedule
(metronomic chemotherapy), leading to significantly less
systemic toxicity [18,19].
Despite these advantages of anti-angiogenic therapy
over conventional chemotherapeutic methods, it still
suffers from certain limitations. For instance, as a result
of systemic administration, most angiogenic inhibitors
often fail to reach the targeted tumor vessels, thus exhi-
biting a poor biodistribution and pharmacokinetic pro-
file, with associated side effects and low efficacy. A great
advance towards this end has come from harnessing the
advantages of nanotechnology to more efficiently target
and kill tumor-associated vasculature. These advantages
are made possible by several parameters, including the
size of these nanoparticles that allows them to intrinsi-
cally home in to metastasized tumors through the
enhanced permeability and retention effect (EPR), their
a b i l i t yt oe v a d et h ei m m u n es y s t e ma n di m p r o v et h e
drug’s half-life significantly thus lowering its effective
dose 50 (ED50), and allow for potent selective targeting
due to their high surface density [15,18,20,21]. For these
reasons, nanotherapeutics are emerging as the new para-
digm for anti-angiogenesis research.
Nanoparticle-mediated anti-angiogenesis therapy for cancer
Nanotechnology in cancer therapy includes an arsenal of
nano-sized materials, generally ranging in dimensions
from 1 nm to a few hundred nanometers in at least one
dimension [22]. These nanoparticles are designed to
carry therapeutic drugs and imaging agents, which are
loaded on or within the nanocarriers by chemical conju-
gation or simply by encapsulation. Nanoparticle based
chemotherapeutic agents are designed such that they
can passively or actively target cancer cells.
The leaky vasculature associated with tumors contri-
butes towards the phenomenon of passive targeting by
nanoparticles. The tumor vessels have increased perme-
ability due to aberrant angiogenesis, thus allowing
nanoparticles with diameters less than 200 nm to pas-
sively extravasate into the tumor sites through the EPR
effect. These nanoparticles are subsequently cleared by
the liver [15,23]. Although many factors, including sur-
face area and chemical modifications, can affect the
nanoparticle biodistribution, size remains the limiting
factor in achieving passive targeting to tumor sites. As
such, nanoparticles with sizes less than 10 nm are
cleared by the kidney, whereas those larger than 200 nm
o f t e na c c u m u l a t ei nt h ee x t r acellular space, and fail to
reach the cancer environment (20). Furthermore, poor
l y m p h a t i cd r a i n a g em e c h a n i s m si nt u m o r sa l l o wt h e
nanoparticles to be retained in the vicinity of the tumor
cells and allow them to release their cargo in a sustained
manner [15]. For example, polymer-conjugated angio-
genesis inhibitor TNP-470 (caplostatin) was found to
accumulate selectively in the tumor vessels by the EPR
effect and inhibit hyperpermeability of tumor blood ves-
sels [24,25]. In studies published from our laboratory,
we have shown that nanoparticle-conjugated chemother-
apeutic agents such as doxorubicin [26,27] and angio-
genic small molecule inhibitors [28] can preferentially
home into tumors by the EPR effect, resulting in selec-
tive vascular shutdown and inhibition of tumor growth.
It should be noted that EPR alone is not always suffi-
cient in targeting the tumor sites and hence is often
used in conjunction with active targeting. This combina-
tion ensures that nanoparticles are retained in the tumor
tissues following their extravasation from leaky vessels.
Active targeting of tumor tissues is achieved by chemi-
cally arraying ligands on the surface of nanoparticles
that can recognize and selectively bind to receptors spe-
cifically expressed on tumor cells and vessels. The high
surface area to volume ratio of the nanoparticles leads
to high local density of ligands for targeting. Nanoparti-
cle-mediated active targeting of the tumor vasculature
in anti-angiogenic therapy has been achieved by target-
ing the VEGF receptors (VEGFRs), aνb3 integrins, and
other angiogenic factors, as discussed briefly in the fol-
lowing section and in more details in each nanovector
category later in this review.
Targeting tumor neovasculature
The most prominent modification of nanovectors entails
covalently conjugating ‘tags’ at their surface, in order to
increase their targeting potential towards tumorogenic
cancer cells and/or their associated vasculature. The
main ‘tag’ used thus far for chemotherapy involves pro-
teins that target the integrin family. As previously men-
tioned, integrins are key players in the angiogenesis
process, and moreover, their upregulation is known to
promote survival, growth, and invasion of both tumor
and endothelial cells [12]. Integrin avb3 has been the
most widely used as a targeting moiety on nanovectors
due to its pleitropic upregulation in a variety of tumor
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translated into several clinical trials [12,33]. However,
important lacunae remain in the field, mainly owing to
the inefficiency of integrin targeting in the long-run.
Nanotechnology-based approaches could remedy this
limitation, due to their prolonged half-life and increased
targeting efficiency. For instance, perfluorocarbon nano-
particles conjugated to various contrasting agents (Gado-
linium, Gd or Fluorine isotope 19,
19F) have successfully
been linked to an avb3 integrin antibody and then visua-
lized by magnetic resonance imaging (MRI) in rabbit and
mouse models of tumor angiogenesis [29,32]. These stu-
dies open the door for non-invasive detection of various
types of cancers in clinical settings, as well as for other
diseases characterized by aberrant vasculature, such as
atherosclerosis and other CVD [31]. In an analogous
manner, another approach to target integrin overexpres-
sion consists of using a synthetic peptide containing the
recognition site for integrins, namely an Arginine-
Glycine-Aspartic acid (RGD) sequence [30]. Recent
studies are further optimizing integrin targeting by
engineering novel peptide moieties which bind with
better affinity to integrins than current RGD tags [34,35].
Another characteristic of tumor-associated vasculature
is inflammation, resulting in upregulation of various
markers known to promote endothelial-tumor cell inter-
actions and metastasis, such as endothelial-cell selectin
(E-selectin) [36]. Although E-selectin-based nanothera-
peutics have been used less extensively than integrin-
targeting nanoparticles, they do provide an additional
means to target activated endothelium, and might hence
provide an attractive tag to be used in conjunction with
integrin targeting [37].
It becomes apparent that targeting-based approaches
for tumor therapies are only as good as the selectivity
and specificity of the targeting moiety used. This, in
turn, implies that using disease-selective markers is cru-
cial in order to obtain maximum selectivity without
deleterious side-effects. Since targeted nanotechnology is
often coupled with a chemotherapeutic agent entrapped
in the nanoparticle, proper targeting to the diseased tis-
sue is crucial to minimize systemic side-effects [38]. As
most diseased states are usually characterized by several
markers, an attractive direction would be to combine
several tags on one nanovector, so long as these do not
interact with each other.
Engineering anti-angiogenic nanoparticles to suit our
needs: Playing with nanovector backbone and drug
coupling for therapeutic and imaging purposes
Since nanoparticles were first proposed by Marty JJ.
et al. in 1978 as novel drug-delivery systems [39], their
use as anti-cancer agents exploded during the 1980 s.
However, only more recently (1995) have they been
used to target angiogenesis [40]. Several nanovectors
have been reported thus far in mediating anti-angiogen-
esis therapy and imaging of the tumor vasculature.
These include an arsenal of synthetic and natural nano-
particles such as polymeric conjugates and polymeric
nanoparticles; liposomes and micelles; synthetic organic
nanoparticles such as dendrimers; carbon-based nanos-
tructures such as carbon nanotubes and polyhydroxy-
lated fullerenes; inorganic nanoparticles of gold, silver
and iron-oxide; quantum dots; viral capsids and ferritin.
The plethora of nanovectors allows researchers to fine-
tune the properties of the drugs depending on their tar-
get. Further fine-tuning is also possible depending on
the method of drug-nanovector coupling, thus offering
the potential to engineer revolutionary therapeutics in
the field of angiogenesis. Herein, we review the different
types of nanovectors that have been studied to formu-
late anti-angiogenic agents for imaging and therapeutic
purposes, their main modifications, as well as their
advantages and limitations.
Polymeric nanoconjugates
A diverse family of polymers has been studied for the
engineering of nanoparticle-based drug delivery agents
since one of the earliest reports in 1979 describing their
use in cancer therapy [41]. Polymers chemically conju-
gated to drugs are regarded as new chemical entities
owing to their distinctive pharmacokinetic profile as
compared to the parent drugs. Polymeric nanoparticles
can also be designed to encapsulate drugs without any
chemical modification. Encapsulated drugs can be con-
trol-released from the polymer matrix by diffusion or
through surface or bulk erosion, while release of conju-
gated drugs requires cleavage of the covalent bonds
under biological conditions. Some key examples of poly-
mer-based nanoconjugates for anti-angiogenesis therapy
have been prepared from structures, such as N-(2-
hydroxypropyl)methacrylamide (HPMA), poly(lactic co-
glycolic acid) (PLGA), polysaccharides (e.g. chitosan)
and dendrimers, to name a few.
N-(2-hydroxypropyl)methacrylamide (HPMA) copoly-
mers HPMA copolymers are hydrophilic substances that
have been extensively studied for their anti-angiogenesis
potential. An HPMA copolymer conjugated to the
angiogenesis inhibitor TNP-470 (Caplostatin), was the
first polymer-conjugated angiogenesis inhibitor reported
[25]. It was found to selectively accumulate in the
tumor microvasculature, resulting in decreased tumor
growth rate in human melanoma and lung carcinoma
mice models. Interestingly, such formulation of TNP-
470 prevented it from crossing the blood-brain barrier,
thus overcoming the neurotoxicity often associated with
chemotherapeutic drugs. The mechanisms of actions
underlying Caplostatin’s chemotherapeutic effects
included inhibition of various angiogenic signaling
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gen-activated protein kinase (MAPK) and RhoA [24].
HPMA copolymers have also been used to design novel
bone-targeted anti-angiogenic therapeutic agents [42,43].
In these studies, the bone-targeting aminobisphospho-
nate drug alendronate (Fosamax) was co-conjugated to
the polymer backbone along with a chemotherapeutic
drug (e.g., paclitaxel, TNP-470), thus inhibiting bone
metastasis. Here, passive targeting was achieved by
extravasation of the nanoconjugates from the leaky
tumor vessels via the EPR effect, while active targeting
to the calcified tissues was achieved by alendronate’s
high affinity to the bone mineral. These studies have
tremendous clinical implications, as bone metastasis is
associated with a plethora of cancers, and its presence
correlates with the terminal stage of cancers.
Specific peptide sequences have been conjugated to
HPMA copolymers for active targeting of the aνb3 integ-
rin in tumor-associated vasculature. Radionuclide-
labeled, cyclized RGD peptide-tagged HPMA copolymer-
based nanoconjugates have been designed that provide
the potential for targeted delivery of radionuclides and
drugs to solid tumors for diagnostic and therapeutic
applications [44,45]. The conjugates exhibited increased
tumor retention times and rapid clearance from normal
tissues, thus reducing systemic toxicity associated
with standard therapeutics. These studies clearly demon-
strated the significance of aνb3 targeting using RGD-
bearing conjugates, as this could provide a promising
strategy for selective delivery of angiogenesis inhibitors
and imaging agents to tumor vasculature and tumor sites
expressing the aνb3 integrin.
Poly(lactic co-glycolic acid) (PLGA) copolymers PLGA
copolymers have been extensively used in the field of
cancer research, owing to their biodegradability and bio-
compatibility, resulting in their FDA approval. PLGA is
synthesized by the co-polymerization of two different
monomers, lactic acid and glycolic acid, and can be
further modified chemically for conjugation or simple
encapsulation of drugs in a nanoparticle formulation, as
s h o w ni nF i g u r e1 .I nas t u d yt a r g e t i n gt h eM A P Ks i g -
naling pathway, Basu and Harfouche et al. have reported
the use of PLGA copolymer for chemically conjugating
PD98059, a selective MAPK inhibitor [46]. The resulting
nanoparticles selectively resulted in melanoma regres-
sion in a mouse model. In a consecutive study, Har-
fouche and Basu et al. encapsulated an inhibitor of the
phosphatidylinositol-3-kinase (PI3K) pathway in a PLGA
copolymer, and used novel zebrafish melanoma and
breast adenocarcinoma tumor xenograft models to
demonstrate its anti-angiogenic effect [28].
PLGA-based nanoparticles have also been used to
engineer complex nanosystems. In a novel strategy
reported by Sengupta et al., temporal targeting of tumor
cells and the tumor vasculature was achieved using a
nanoscale delivery system, described as a ‘nanocell’,t h a t
comprised of a core PLGA nanoparticle encapsulated
within a polyethylene glycol (PEG)-linked lipid envelop
[26]. PEGylation of a molecule renders the latter non-
toxic and non-immunogenic, and is an FDA approved
method [47]. In this nanostructure, the chemotherapeu-
tic drug doxorubicin was covalently attached to the
inner PLGA core, and the anti-angiogenic agent com-
bretastatin was trapped within the outside lipid envel-
ope. After disruption of the outer envelope inside a
tumor, release of combretastatin led to vascular collapse
and intra-tumoral trapping of the nanoparticles, which
subsequently released the chemotherapeutic drug in
response to local hypoxia, resulting in significant regres-
sion of various tumors including melanoma. The nano-
cell is an example of nanoparticles being engineered
based on understanding of the disease, and can be fine-
tuned to optimize chemotherapy, thus shifting the para-
digm from conventional anti-angiogenic treatments.
In our ongoing studies using a Zebrafish mutant,
named Casper, which allows the visualization of cancer
cells in real-time even when they are unlabeled [48], we
demonstrated that hybrid nanoparticles of PLGA carry-
ing an inhibitor of PI3K not only inhibited vasculariza-
tion, as shown by reduced subintestinal vessel (SIV)
density, but also inhibited both human melanoma and
breast adenocarcinoma tumor cell growth (Figure 2).
PLGA nanoparticles have not only been used as delivery
agents of synthetic drugs, but have also recently been
described for delivering natural products thought to have
anti-cancer effects. Curcumin (yellow pigment in the spice
turmeric)-loaded PLGA nanoparticles were reported
to successfully suppress tumor necrosis factor (TNF)-
regulated expression of VEGF, culminating in reduced
tumor metastasis [49]. This approach is promising for
Figure 1 PLGA nanoparticles: (A) Chemical conjugation or simple
encapsulation of chemotherapeutic agents in PEG-modified PLGA
nanoparticles. (B) Transmission electron microscopy image of PLGA
nanoparticles. Scale bar: 100 nm.
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nates many side-effects observed with synthetic drugs.
Polysaccharides and Dendrimers Polysaccharides (e.g.
chitosan) and dendrimers can also be considered as
polymeric systems, and have been studied as carriers of
anti-angiogenic agents for therapeutic applications. Chit-
osan is a commercially available cationic linear polysac-
charide, which has found a variety of applications in
pharmaceuticals and biomedicine. Dendrimers, on the
other hand, possess a branched structure that provides
it with certain unique properties like ease of chemical
conjugation, biocompatibility, high water-solubility and
easy renal clearance due to their small size [15,50]. Dif-
ferent dendrimeric systems are now under investigation
for novel cancer treatments [50]. In a recent study, chit-
osan nanoparticles have shown significant inhibition of
tumor growth and induction of tumor necrosis in a
mouse hepatocellular carcinoma xenograft model [51].
The anti-tumor activity of these nanoparticles was
found to be related with their anti-angiogenic activity,
which was linked to significant reduction in the levels of
VEGFR-2 expression and subsequent blockage of VEGF-
induced endothelial cell activation. In using dendrimers
as nanovectors, Backer et al. have described the con-
struction of VEGF121-containing, boronated polyamidoa-
mine dendrimer that can be used to target VEGF
receptors on tumor neovasculature [52]. Near-IR fluor-
escent imaging of mouse breast carcinoma revealed
selective accumulation of these dendrimers in the per-
iphery of growing tumors, where tumor neovasculariza-
tion was most prominent. These studies demonstrate
the potential of designing chitosan and dendrimer-based
nanoparticles for both chemotherapeutic and imaging
purposes.
Lipid-based nanoparticles
Lipid-based nanocarriers, such as liposomes and micelles,
possess attractive biological properties, including bio-
compatibility, biodegradability, and the ability to entrap
both hydrophobic and hydrophilic drugs [15]. Liposomes
are FDA-approved spherical structures consisting of
phospholipid bilayers with an enclosed aqueous phase
that can carry a range of chemotherapeutic drugs.
Micelles, on the other hand, consist of lipid monolayers
with a hydrophilic shell enclosing a hydrophobic core in
a spherical structure. Although liposomal nanosystems
have been widely reported for anti-angiogenic therapy,
reports on using micelles are relatively fewer. Benny
et al. reported that conjugation of the angiogenesis inhi-
bitor TNP-470 to monomethoxy-polyethyleneglycol-
polylactic acid copolymer resulted in the formation of
nanopolymeric micelles, named Lodamin [53]. On oral
administration, the conjugate was found to accumulate
selectively in tumors, inhibiting tumor growth, angiogen-
esis and proliferation, without causing any neurological
impairment in tumor-bearing mice. In another study
based on targeting the aνb3 integrin, Nasongkla et al.
designed a cyclic RGD pentapeptide conjugated, doxoru-
bicin-loaded poly(ε-caprolactone)-polyethyleneglycol
(PCL-PEG) nanopolymeric micelles [54]. The micelles
showed high efficiency in targeting SLK tumor endothe-
lial cells derived from human Kaposi’s sarcoma in vitro.
Since most chemotherapeutics are delivered in highly
invasive manners, such as by systemic injection, this
method of targeted delivery has the crucial capacity of
immensely reducing discomfort and cytotoxicity in the
patient.
Adding to the library of peptide-tags for targeting is a
pentapeptide sequence consisting of the amino acids Ala-
nine-Proline-Arginine-Proline-Glycine (APRPG), that has
been isolated from a phage-displayed peptide library and
has been found to specifically bind to tumor angiogenic
vasculature [55]. APRPG-conjugated liposomal nanosys-
tems containing chemotherapeutic drugs have been stu-
died for their vasculature-targeting anti-angiogenic
effects [56,57]. These studies demonstrated the benefits
of using the APRPG-motif for active targeting of drug
Figure 2 Effects of LY-encapsulated PLGA nanoparticles in vivo
using Casper Zebrafish-breast adenocarcinoma xenograft
assay. (A) Real-time imaging. Broken arrows show cancer cells. (B)
Alkaline phosphatase vessel staining. Full arrows show subintestinal
vessels (SIV). (C) Quantification of SIV using morphometric analyses
developed in our laboratory. HNP = hybrid nanoparticles. P
# ≤ 0.05
versus wild-type and empty nanoparticle controls. (In collaboration
with Dr. Richard M. White and Dr. Leonard I. Zon, Children’s Hospital
Boston).
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modality, namely anti-neovascular therapy [58].
Due to their ease of synthesis, liposomal systems have
been used to target a plethora of angiogenic factors,
including VEGFRs, aνb3 integrins and matrix metallo-
proteinases (MMPs). Li et al. investigated the potential
anti-angiogenic efficacy of two polymerized liposomal
nanoparticles radiolabeled with Yttrium isotope 90
(
90Y), one conjugated to a small molecule integrin
antagonist targeting the aνb3 integrin and the other
loaded with a monoclonal antibody against murine
VEGFR-2 receptor Flk-1 [59]. Membrane type-1 matrix
metalloproteinase (MT1-MMP), expressed on angio-
genic endothelium cells and tumor cells, also plays an
important role in angiogenesis. Hatakeyama et al.
designed Fab’ fragments of anti-human MT1-MMP
monoclonal antibody conjugated to PEG-modified dox-
orubicin-encapsulating liposomes that showed signifi-
cant decrease in tumor volume in vivo as compared to
the non-targeted liposomes [60].
Carbon nanovectors
Carbon-based nanostructures, such as carbon nanofibers,
nanotubes and fullerenes, have received considerable
attention for cancer research in the past. This is due to
several advantages, including: (1) high mechanical
strength and surface area, (2) numerous sites for chemi-
cal or physical conjugation, (3) light weight properties,
and (4) ease of scalability and manufacturing [61].
However, issues related to their biocompatibility, renal
clearance and toxicology have since limited their use in
biomedical applications. In addition, although an increas-
ing number of studies have been reported on the use of
carbon nanovectors in cancer research, their use in tar-
geting angiogenesis remains limited.
Murugesan et al. have reported the efficacy of multi-
walled carbon nanotubes, C60 fullerenes and graphite in
inhibiting VEGF- and bFGF-induced angiogenesis in
chick chorioallantoic membrane (CAM) [61]. These car-
bon materials did not have any significant effect on basal
angiogenesis in the absence of added growth factors,
indicating potential in tumor environment where angio-
genic factors are known to be upregulated. In an interest-
ing study, Chaudhuri et al.r e p o r t e dt h a tt h es h a p eo f
carbon-based nanostructures markedly affects the che-
motherapeutic potential of doxorubicin [27]. The authors
showed differential effects between doxorubicin (Dox)
conjugated to single-walled carbon nanotubes (CNT) ver-
sus spherical fullerenols (Full) on angiogenesis (Figure 3).
Both empty and Dox-conjugated fullerenols exerted anti-
angiogenic effects in zebrafish and mouse melanoma
models. In contrast, empty and Dox-conjugated CNTs
exerted a pro-angiogenic effect both in vitro and in vivo.
Mechanistic studies implicated differential activation of
aνb3 integrins and downstream PI3K signaling between
CNT and fullerenol in endothelial cells, which implicates
the role of nanovector shapes in mediating drug fate, and
Figure 3 Effects of doxorubicin (Dox)-conjugates of fullerenols and carbon nanotubes (CNT) on B16-F10 mediated angiogenesis in
mouse xenograft model. Angiogenesis was assessed by immunodetection of the Von Willebrand Factor (vWF) endothelial cell marker (green)
and propidium iodide counterstain (red) on treatments with: (A) control; (B) fullerenol; (C) CNT; (D) Dox alone; (E) fullerenol-Dox conjugate; and
(F) CNT-Dox conjugate.
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obtain optimal therapeutic index.
Inorganic nanoparticles
Inorganic nanoparticles, such as the ones derived from
gold, silver and iron-oxide, possess unique optical, elec-
trical, magnetic, and photothermal properties, which
have been harnessed in numerous biomedical applica-
tions. Recently, they have been reported for use in anti-
angiogenic therapy also.
Mukherjee et al. observed that gold nanoparticles bind
specifically with heparin-binding growth factors, such as
VEGF165 and bFGF, resulting in inhibition of endothelial
cell proliferation in vitro, and VEGF-induced permeabil-
ity and angiogenesis in vivo, but failed to inhibit the
activity of non-heparin binding growth factor VEGF121
[62]. Gurunathan et al. reported on the anti-angiogenic
properties of silver nanoparticles, and demonstrated that
these agents could inhibit VEGF-induced cell prolifera-
tion, migration and formation of new blood microvessels
in vivo [63]. Furthermore, their results indicated that sil-
ver nanoparticles could target the activation of PI3K/
Akt signaling pathways, thus leading to the inhibitory
effect of angiogenesis.
T h ep a r a m a g n e t i cp r o p e r t i e so fi r o n - o x i d en a n o p a r t i -
cles have been harnessed for therapeutic and imaging
applications [64]. Chen et al. have reported that dextran-
coated iron-oxide nanoparticles conjugated to radiola-
beled (Iodine isotope 131,
131I) anti-VEGF monoclonal
antibody significantly increased imaging resolution as
well as destruction of liver cancer in mice [65]. Maeng
et al. have developed doxorubicin-loaded, folate-receptor
targeted superparamagnetic iron oxide nanoparticles that
significantly inhibited tumor growth, yet surprisingly,
did not increase systemic cytotoxicity often associated
with heavy metals, most likely due to their selective
localization in tumors [66].
Imaging tumor angiogenesis
Medical imaging has undergone tremendous research
and development over the past few decades, with the
introduction of techniques such as magnetic resonance
imaging (MRI), computed tomography (CT), ultrasono-
graphy, nuclear medicine scanning, and optical fluores-
cence imaging [67,68]. The possibility of non-invasive
and accurate monitoring of tumor response has led to
growing interest in the use of these techniques in angio-
genesis research. Use of nanoparticles offer several
advantages in this area of research, including their cap-
ability of carrying high payloads of therapeutic and diag-
nostic agents, improved contrast, and longer circulation
times in the body.
MRI has been found to correlate more directly with
tumor angiogenesis as compared to other imaging tech-
niques [67]. Drevs et al. have reported the use of the
dynamic enhanced MRI technique for studying the
effects of PTK787/ZK 222584, a specific VEGF receptor
tyrosine kinase inhibitor, on the anatomy and functional
properties of tumor vessels [69]. Dextran-associated,
superparamagnetic iron oxide nanoparticles (Endorem)
were used in this study to detect the partial tumor
blood volume in a murine renal cell carcinoma model.
Reichardt et al. have also used the MRI technique and
superparamagnetic nanoparticles in imaging the anti-
angiogenic effects of a small molecule VEGF receptor
tyrosine kinase inhibitor in a drug-resistant human ade-
nocarcinoma model [70]. Sipkins et al. have pioneered
the use of endothelial aνb3-targeted, gadolinium ion-
containing paramagnetic liposomes for imaging tumor
angiogenesis by MRI [71]. Intravenous administration of
these nanoparticles provided detailed and enhanced ima-
ging of the aνb3 expressing tumor vasculature in rabbit
carcinomas.
A combination of two or more modalities, either in
imaging or in therapeutic applications, or both, can
function synergistically to provide complementary infor-
mations. A bimodal approach to imaging tumor angio-
genesis, using MRI and fluorescence, was reported by
Mulder et al [72]. In a following study, the same bimo-
dal liposomal system was used for non-invasive evalua-
tion of the therapeutic efficacy of angiogenesis inhibitors
anginex and endostatin [73]. In a novel approach, Kluza
et al. have functionalized a bimodal (MRI- and fluores-
cence-detectable) paramagnetic liposomal nanoparticle
with two angiogenesis-specific targeting ligands - an
aνb3-specific RGD peptide sequence and a galectin-1-
specific designer peptide anginex [74]. This strategy of
dual ligand targeting provided synergistic targeting
effects in vitro significantly improving the uptake of
these nanoparticles as compared to those modified for
single ligand targeting.
A p a r tf r o mM R Ia n do p t i c a limaging, liposomes have
also been used to encapsulate contrast agents for CT
imaging. For example, Samei et al. have reported the
use of a long-circulating liposomal system encapsulating
traditional iodinated contrast agent for micro-CT
imaging of rats implanted with R3230AC mammary
carcinoma [75].
Quantum dots (QDs), which are fluorescent nanocrys-
tals made of inorganic semiconductor materials, have
gained prominence in biomedical imaging due to their
unique photostable and fluorescence properties. We
observed that QD complexes, conjugated to aνb3 integ-
rin-binding cyclic RGD peptide for endothelial cell tar-
geting in vitro, showed increased uptake into the cells as
compared to QDs that were conjugated to a control
RAD (Arginine-Alanine-Aspartic acid) peptide (negative
control) (Figure 4).
Paramagnetic QDs have been engineered as a bimodal
(MRI and fluorescence) imaging probe. Such QDs
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used for successful targeting of human endothelial cells
in vitro [76]. In another study, paramagnetic QDs on
conjugation with a cyclic peptide that can target CD13,
an aminopeptidase highly overexpressed on angiogenic
tumor endothelium, enabled quantitative molecular MRI
of tumor angiogenesis in vivo [77].
Natural nanoparticles, such as viruses and ferritin,
have several advantages over synthetic nanoparticles,
including precise dimensions, possible evasion by the
immune system, biocompatibility and biodegradability
[68]. A number of viral nanoparticles (VNPs) have been
developed for targeted delivery and imaging purposes, e.
g. cowpea mosaic virus (CPMV) and bacteriophages
such as MS2, Qb, and their modes of cellular uptake
have been studied [78]. Banerjee et al. have recently
reported the mechanism of receptor-mediated endocyto-
sis of transferrin-decorated bacteriophage Qb [79]. Mul-
tivalent display of fluorescent tags on CPMV facilitated
intravital visualization of human fibrosarcoma-mediated
tumor angiogenesis in a CAM model [80]. In a different
study, covalent attachment of a VEGF receptor-1 speci-
fic peptide to fluorescently labeled CPMV enabled effi-
cient targeting of the VNPs to VEGFR-1-expressing
tumor in vivo [81].
Apart from viral nanoparticles, protein cages such as
the iron-containing ferritin have also been studied in
medical imaging [68]. Crich et al. have reported the
MRI visualization of tumor angiogenesis in vivo by tar-
geting the neural cell adhesion molecules expressed on
tumor endothelium with a highly sensitive gadolinium-
containing apoferritin probe [82].
New generation research in anti-angiogenesis therapy
Apart from the more conventional approaches of array-
ing small molecule chemotherapeutic drugs or antibo-
dies on different synthetic or natural nanovectors to
achieve anti-angiogenic effects, new research reports are
emerging that target the molecular mechanism of angio-
genesis by using approaches such as gene silencing and
Figure 4 PEGylated Quantum Dot (QD) nanocrystals conjugated to aνb3-specific RGD peptide for endothelial cell targeting; (A) low
resolution transmission electron microscopy image showing the nanoconjugates, the arrow indicating one such nanostructure; (B and C)
spinning disk confocal microscopy images showing uptake of RGD-targeted QD clusters in endothelial cells treated with cations that are known
to cause integrin clustering. Incubation with the RAD-PEG-nanocrystal QD clusters showed no uptake by the cells (B), while RGD-PEG-nanocrystal
QD clusters resulted in increased uptake into the cells (C).
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these emerging new strategies.
Nanoconjugates for siRNA/gene delivery
An interesting strategy to target tumor vasculature is by
systemic delivery of an anti-angiogenic gene using a
nanoconjugate system. The soluble fragment of VEGF
receptor Flt-1 (sFlt-1) is a potent and selective inhibitor
of VEGF. As such, Kim et al. showed that the stable
expression of sFlt-1 by endothelial cell targeted gene
delivery inhibited angiogenes i s[ 8 3 ] .F o rt h i sp u r p o s e ,
the authors designed a PEGylated polyethyleneimine
(PEI) nanosystem, consisting of the aνb3 integrin target-
ing RGD peptide sequence, PEI-g-PEG-RGD, and com-
plexed with the therapeutic gene encoding sFlt-1. The
PEI-g-PEG-RGD/pCMV-sFlt-1 nanoconjugate system
successfully inhibited the proliferation of cultured
endothelial cells in vitro by blocking the binding of
VEGF to the membrane-bound full length Flt-1 recep-
tor. In a further study, the authors showed that this
polymeric gene delivery system reduced tumor burden
in mice while increasing prognosis [84].
The use of small interfering RNA (siRNA) and short-
hairpin RNA (shRNA) have tremendously helped in our
understanding of the molecular mechanisms underlying
angiogenesis and tumor developments. The high specifi-
city of these small RNA sequences in binding target
proteins post-transcriptionally can prove crucial to our
efforts in designing new generation of therapeutics [85].
In one such study, Schiffelers et al.h a v er e p o r t e dt h e
engineering of RGD-sequence bearing PEGylated self-
assembling polymeric nanoparticles that can be used to
deliver siRNAs specifically targeted to inhibit VEGFR-2
expression, thereby inhibiting tumor angiogenesis [86].
Intravenous administration of these nanoparticles into
mice bearing neuroblastoma N2A tumors led to selec-
tive tumor uptake, siRNA sequence-specific inhibition of
VEGFR2 expression in tumor, and inhibition of tumor
growth and angiogenesis.
Lipid-based nanosystems have also been reported for
targeted gene and siRNA delivery. Protease-activated
receptor-1 (PAR-1) siRNA incorporated into neutral
liposomes was used to target the thrombin receptor
PAR-1, which is involved in adhesion, invasion and
angiogenesis [87]. Systemic delivery of these nanoparti-
cles inhibited both melanoma tumor growth and metas-
tasis in mice. This led to significant inhibition of tumor
growth and weight, in addition to a concomitant
decrease in the expression of various angiogenic factors
(VEGF, interleukin-8 and MMP-2), as well as reduced
blood vessel density.
Apart from polymeric and lipid-based nanosystems,
chitosan nanoparticles loaded with siRNA have also been
designed to provide a novel therapeutic tool for selectively
knocking down angiogenesis genes. For instance, Pillé
et al. have reported the use of a chitosan-coated poly-
isohexylcyanoacrylate nanoparticle for encapsulating
anti-RhoA siRNA, resulting in inhibition of tumor growth
and angiogenesis in an aggressive breast cancer mouse
xenograft model [88].
Aptamers
Aptamer-based nanotherapeutics have emerged as a
novel strategy due to their recognition, and hence tar-
geting, of an endless list of moieties including onco-
genes, viruses, bacteria and inflammatory proteins.
Aptamers are short, three-dimensional synthetic RNA or
DNA oligonucleotides (15-40 nucleotides long) or pep-
tides (10-20 amino acids long) that bind their target
with high affinity and specificity, hence their nickname
of ‘chemical antibodies’ [89-91]. Depending which epi-
tope aptamers bind to, namely an active versus non-
active site, determines whether aptamers inhibit function
or simply acts as a targeting moiety. These properties
make aptamers ideally suited for diagnostics, imaging
and targeting of angiogenic-based pathologies. The
strengths of aptamers reside in their versatility, non-
immunogenicity, low cost, high reproducibility and ease
of production, which become immediately apparent
when compared with standards antibodies. For instance,
oligonucleotide and peptide aptamers can be isolated
from an impressively large repertoire of libraries, by pro-
cesses known as Systematic Evolution of Ligands by
Exponential Enrichment (SELEX) and yeast/bacterial
expression libraries, respectively [89,91]. These libraries
have been key determinants in increasing the efficacy
and popularity of aptamer-based nanotechnology, as
they allow high-throughput screening and can hence
find disease markers. The main lacuna of aptamers are
that they are easily degraded by cellular nucleases and
proteinases [89]. This lacuna is easily remedied by che-
mical modifications of the aptamers, making them ideal
candidate for novel nanotherapeutics with improved tar-
geting power and therapeutic index [90].
Oligonucleotide aptamers have recently gained much
popularity in the field of cancer in general. For instance,
they have played a crucial role in increasing targeting and
imaging of cancer cell and their associated vasculature by
being coupled to metallic nanoparticles such as magnetic,
gold and ruby-eye doped nanoparticles, as well as quan-
tum dots [90,92-94]. This coupling of aptamers to metal-
lic nanoparticles creates an exciting new opportunity for
tumor detection, as it potentiates the biosensor capability
of metallic nanoparticles significantly. Using other type
of nanovectors, VEGF-targeting RNA aptamers have
been combined with either PLGA microspheres or
1,2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC)
and cholesterol nanoliposomes, resulting in potent and
selective inhibition of angiogenesis in vitro and in vivo
for prolonged time periods [95,96]. In another interesting
Banerjee et al. Vascular Cell 2011, 3:3
http://www.vascularcell.com/content/3/1/3
Page 9 of 13study, an Ang-2 RNA aptamer was shown to inhibit adult
neovascularization in a rat corneal pocket model of
tumor angiogenesis [97]. As the role of Ang-2 in mediat-
ing vascularization has long been contested, with contra-
dicting reports demonstrating both pro- and anti-
angiogenic roles, this study validates our previous find-
ings that Ang-2 can indeed play a preponderant role in
promoting angiogenesis [98].
Oligonucleotide aptamers have preferentially been used,
as compared with their peptide counterparts, mainly due
to their higher binding affinities and lower costs and ease
of synthesis and purification. This has translated into very
few reports combining peptide aptamer- and nanoparticle-
based technologies, with most studies instead focusing on
the advantages of these aptamers for forward and reverse
genetic experiments [91]. Hence, there is currently an
enormous gap with respect to peptide aptamer-based
nanotherapeutics, altough the potential is certainly pre-
sent, mainly due to the advantage of peptide aptamers in
disrupting protein-protein interactions. As such, they have
efficiently been used in cancer setting to target and inhibit
various tumor markers associated with tumor growth and
metastasis [99,100]. Although these latter studies didn’t
conjugate the aptamers with nanovectors, they open up
the doors to novel and exciting possibilities in the nano-
technology field. To the best of our knowledge, peptide
aptamers have only been conjugated with nanomaterials in
the case of carbon, but for the sole purpose of increasing
its solubility [101].
Stem cell-based nanotherapeutics
In a novel approach, embryonic stem cells have been used
in conjunction with nanoparticles for either tumor imaging
[102] or for pro-angiogenic therapy during CVD-related
ischemia [103]. For imaging, stem cells were labeled with
ferumoxides-poly-lysine complexes (e.g. iron oxide super-
paramagnetic nanoparticles) and used to visualize gliomas
using MRI. This finding has enormous therapeutic implica-
tions, since very few agents are able to bypass the blood
brain barrier, often resulting in insurmountable obstacles
for the treatment of brain malignancies. Regarding pro-
angiogenic stem cell-based therapeutics, cells were trans-
fected with VEGF DNA using biodegradable poly(b-amino
esters) nanoparticles, leading to significant vascular regen-
eration in ischemic tissues [103]. This methodology in itself
is quite novel, as standard transfection methods rely on
plasmids or electroporation, which results in high cell
stress and low efficiency. Although there are very few stu-
dies merging nanotechnology with stem cells, this field
warrants further investigation due to its immense clinical
potential in a variety of angiogenic diseases, especially
those characterized by vessel insufficiency. In a novel
approach, our laboratory has attempted to merge the use
of carbon nanovectors with embryonic stem cells. Our pre-
liminary results show that the shape of carbon nanostruc-
tures can modulate stem cell fate, with an example of an
inhibitory effect on vascularization, as shown in Figure 5.
Our ongoing studies underlie the infinite possibilities of
Figure 5 Carbon nanovectors inhibit stem cell-mediated vascularization. Immunocytochemistry results show Von Willebrand Factor (vWF)
endothelial cell marker (red) and DAPI counterstain (blue).
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but structure as well.
Concluding Remarks and Future Directions
The tumor neovasculature is an attractive target for
anti-angiogenic therapy as well as non-invasive imaging
studies. Nanotechnology has emerged as an exciting
field in this area of research due to multiple advantages,
including the capacity of nanoparticles to carry multiple
moities of therapeutic and imaging agents, offer longer
circulation time and increase the therapeutic index of
chemotherapeutcs, to name a few. Moreover, with the
various types of nanovectors available, many of which
are FDA-approved, along with the various methods for
coupling them to drugs and diagnostic agents, there is
an endless opportunity to fine-tune nanotherapeutics
depending on the task needed. Clearly, the advent of
nanothechnology provides a huge potential for devising
increasingly novel anti-angiogenic therapeutics that can
eventually be translated from bench to bed-side.
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